• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease.

作者信息

Orfanoudaki Eleni, Foteinogiannopoulou Kalliopi, Theodoraki Eirini, Koutroubakis Ioannis E

机构信息

Department of Gastroenterology, University Hospital of Heraklion, Heraklion, Crete, Greece.

出版信息

Inflamm Bowel Dis. 2020 May 12;26(6):e50. doi: 10.1093/ibd/izaa061.

DOI:10.1093/ibd/izaa061
PMID:32206807
Abstract
摘要

相似文献

1
Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2020 May 12;26(6):e50. doi: 10.1093/ibd/izaa061.
2
Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.与反应性监测相比，积极监测英夫利昔单抗血清浓度可改善炎症性肠病患者的长期预后。
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1580-1588.e3. doi: 10.1016/j.cgh.2017.03.031. Epub 2017 Mar 30.
3
Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.英夫利昔单抗降阶梯治疗炎症性肠病患者复发的预测因素：基于治疗药物监测策略的价值。
Aliment Pharmacol Ther. 2019 Jan;49(2):147-154. doi: 10.1111/apt.15046.
4
Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.主动英夫利昔单抗药物监测优于炎症性肠病的常规治疗。
Inflamm Bowel Dis. 2020 Jan 6;26(2):263-270. doi: 10.1093/ibd/izz131.
5
Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.检测耐药物抗体对英夫利昔单抗的临床相关性：TAXIT 试验的事后分析。
Gut. 2018 May;67(5):818-826. doi: 10.1136/gutjnl-2016-313071. Epub 2017 Apr 27.
6
The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.英夫利昔单抗治疗药物监测在炎症性肠病患者中的应用及对疗效丧失的关注：真实世界经验的回顾性分析。
Can J Gastroenterol Hepatol. 2016;2016:5203898. doi: 10.1155/2016/5203898. Epub 2016 Nov 10.
7
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease.八种英夫利昔单抗群体药代动力学模型在荷兰炎症性肠病儿童队列中的表现。
Clin Pharmacokinet. 2024 Apr;63(4):529-538. doi: 10.1007/s40262-024-01354-7. Epub 2024 Mar 15.
8
Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.采用新西兰检测方法评估英夫利昔单抗和阿达木单抗浓度及抗药物抗体对炎症性肠病的控制效果。
Intern Med J. 2019 Apr;49(4):513-518. doi: 10.1111/imj.14064.
9
Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.采用即时检测设备测定炎症性肠病患儿血清英夫利昔单抗浓度。
J Pediatr Gastroenterol Nutr. 2019 Oct;69(4):474-479. doi: 10.1097/MPG.0000000000002410.
10
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.英夫利昔单抗的原发性和继发性无应答：机制与对策
Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1039-1046. doi: 10.1080/17425255.2017.1377180. Epub 2017 Sep 11.